Digest Network Come funziona
Network
/
Società
Sp
Non verificato

SpringWorks Therapeutics, Inc.

Di cosa scriviamo

Annunci EconomiciBiotecnologiaFinanzaMedicina Salute Benessere

8 comunicati stampa

Guarda tutti i comunicati
20/10/2025
Biotecnologia
Annunci Economici
SpringWorks Therapeutics Announces Publication of Long-Term Efficacy and Safety Data from the Phase 3 DeFi Trial of OGSIVEO® (nirogacestat) in Adults with Desmoid Tumors in the Journal of Clinical Oncology
Fonte
SpringWorks Therapeutics, Inc.
Emittente
GLOBENEWSWIRE
1.00
0
18/08/2025
Biotecnologia
Medicina Salute Benessere
Annunci Economici
European Commission Grants Approval of OGSIVEO® (nirogacestat) for the Treatment of Adults with Desmoid Tumors
Fonte
SpringWorks Therapeutics, Inc.
Emittente
GLOBENEWSWIRE
1.00
0
18/07/2025
Biotecnologia
Medicina Salute Benessere
Finanza
European Commission Grants Conditional Approval of EZMEKLY® (mirdametinib) for the Treatment of Adult and Pediatric Patients with NF1-PN
Fonte
SpringWorks Therapeutics, Inc.
Emittente
GLOBENEWSWIRE
1.00
0
20/06/2025
Biotecnologia
Medicina Salute Benessere
SpringWorks Therapeutics Receives Positive CHMP Opinion for Nirogacestat for the Treatment of Adults with Desmoid Tumors
Fonte
SpringWorks Therapeutics, Inc.
Emittente
GLOBENEWSWIRE
1.00
0
24/05/2025
Biotecnologia
Medicina Salute Benessere
SpringWorks Therapeutics recibe un dictamen positivo del CHMP para el uso de mirdametinib en el tratamiento de la NF1-NP en pacientes adultos y pediátricos
Fonte
SpringWorks Therapeutics, Inc.
Emittente
GLOBENEWSWIRE
1.00
0
24/05/2025
Biotecnologia
Medicina Salute Benessere
SpringWorks Therapeutics: CHMP valuta positivamente Mirdametinib per il trattamento di pazienti adulti e pediatrici affetti da NF1-PN
Fonte
SpringWorks Therapeutics, Inc.
Emittente
GLOBENEWSWIRE
1.00
0
24/05/2025
Biotecnologia
Medicina Salute Benessere
SpringWorks Therapeutics reçoit un avis favorable du CMUH pour l’utilisation du mirdamétinib pour le traitement des patients adultes et pédiatriques atteints de NF1-PN
Fonte
SpringWorks Therapeutics, Inc.
Emittente
GLOBENEWSWIRE
1.00
0
23/05/2025
Biotecnologia
Medicina Salute Benessere
SpringWorks Therapeutics Receives Positive CHMP Opinion for Mirdametinib for the Treatment of Adult and Pediatric Patients with NF1-PN
Fonte
SpringWorks Therapeutics, Inc.
Emittente
GLOBENEWSWIRE
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0